Agathos Biologics is pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy.
Our mission as The Good Science Company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone.
In 2019 NIH funded $109 million of research projects involving fetal tissue. The NIH reversed restrictions on fetal tissue research and cancel an ethics review of grant proposals. Use of aborted fetal tissue will remain controversial–the only solution is to create alternatives.
Rates of non-medical vaccine exemption are increasing anywhere from 20% – 500%. Nonmedical vaccine exemption rates rose 19 percent between 2009 and 2013, nearly doubled in Texas, and religious exemptions in New Jersey increased 5X from 2006 to 2014. Ethically manufactured vaccines could reduce these numbers significantly.
86% of large employers are concerned about the impact of million-dollar treatments being approved by the FDA Most of these treatments are produced in living cells – lack of scalability of existing cell lines, including HEK293, is “the main challenge” for expensive gene therapies. We have to do better with better, ethically-developed cells.
